Acutus Medical announces $170 million financing
advertisement

Acutus Medical announces $170 million financing

Press releases may be edited for formatting or style | June 21, 2019 Business Affairs Cardiology
CARLSBAD, Calif., June 20, 2019 /PRNewswire/ -- Acutus Medical today announced a $170 million financing, including a $100 million Series D equity financing and a $70 million credit facility. The funding is intended to accelerate commercialization and facilitate global business development activities as the company continues to transform arrhythmia care through distinct, innovative technologies designed to provide physicians and patients with improved results.

The Series D equity financing round included new investors 8VC, Opaleye Management, Pura Vida Investments, among others. The round also included strong participation from existing investors including OrbiMed, Deerfield Management Company, Advent Venture Partners, Xeraya Capital and GE Ventures. The credit facility was provided by OrbiMed Credit and Royalties Fund and Deerfield Management.

Acutus provides next-generation electrophysiology technology solutions that can enable personalized and adaptive approaches to therapy. Acutus' AcQMap is the first and only cardiac imaging and mapping system that incorporates precision ultrasound atrial anatomy reconstruction and highly reproducible, high-definition non-contact charge density mapping. The system also provides workhorse contact mapping capabilities, available in Europe. AcQMap's increased clarity of arrhythmia pattern mapping aids in the development of patient specific ablation strategies. Unique to this system, physicians can rapidly remap and confirm the impact of each ablation.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

Tens of millions of people worldwide suffer from cardiac arrhythmias.1 Arrhythmias cause the heart to beat too quickly, slowly or erratically, which can result in debilitating symptoms and, in some instances, fatal consequences.2 According to the Centers for Disease Control and Prevention (CDC), as many as 6.1 million Americans may be living with the most common type of arrhythmia, atrial fibrillation (AF), which incrementally costs the United States approximately $26 billion each year.3 Acutus' focus is treating and reducing the burden of atrial arrythmias through cardiac access, diagnostics, monitoring and innovative mapping and visualization technology. Recent clinical science shows that cardiac ablation of atrial arrhythmias within six months of diagnosis results in better patient outcomes.4

"This round of financing is a clear demonstration of confidence in our strategic direction and ability to disrupt the electrophysiology space by delivering advanced, innovative technologies to our customers," said Vince Burgess, CEO, Acutus Medical. "Advanced imaging, individualized therapy and increased procedural efficiency are needed components to progress the electrophysiology field. We are dedicated to improving every aspect of cardiac ablation, as evidenced by our recent closing of the acquisition of Rhythm Xience to provide a novel suite of products designed to improve the safety and speed of left atrial access."

You Must Be Logged In To Post A Comment